TABLE OF CONTENTS
Themed issue: CB2 Receptors
- Themed issue:
- January 2008 Volume 153, No 2
This issue has been edited by Ruth Ross and Ken Mackie and contains 16 review articles and 5 original articles which seek to give further insight into the function and role of the hitherto enigmatic CB2 receptor. The meeting "CB2 cannabinoid receptors: New vistas" was held in Banff, Canada in 2007 and was organized by Keith Sharkey, Ken Mackie, Betty Yao, Marnie Duncan and Ruth Ross. This meeting was designed to bring together scientists studying CB2 receptors from diverse perspectives, including those interested in the chemistry of CB2 ligands, the role of CB2 receptors in normal biological processes, and the involvement of CB2 receptors in pathological processes.
Commentary
Good news for CB1 receptors: endogenous agonists are in the right place FREE
M Maccarrone
Br J Pharmacol 153: 179-181; advance online publication, November 12, 2007; doi:10.1038/sj.bjp.0707566
See also: Research Paper by Rimmerman et al.Review Article
Cannabinoid receptors and the regulation of bone mass FREE
I Bab and A Zimmer
Br J Pharmacol 153: 182-188; advance online publication, December 10, 2007; doi:10.1038/sj.bjp.0707593
See also: Commentary by Mackie & RossCB2 receptors in reproduction FREE
M Maccarrone
Br J Pharmacol 153: 189-198; advance online publication, September 10, 2007; doi:10.1038/sj.bjp.0707444
See also: Commentary by Mackie & RossThe diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: 
9-tetrahydrocannabinol, cannabidiol and 9-tetrahydrocannabivarin FREE
R G Pertwee
Br J Pharmacol 153: 199-215; advance online publication, September 10, 2007; doi:10.1038/sj.bjp.0707442
See also: Commentary by Mackie & RossCB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies FREE
Á Arévalo-Martín, D García-Ovejero, O Gómez, A Rubio-Araiz, B Navarro-Galve, C Guaza, E Molina-Holgado and F Molina-Holgado
Br J Pharmacol 153: 216-225; advance online publication, September 24, 2007; doi:10.1038/sj.bjp.0707466
See also: Commentary by Mackie & RossBiology and therapeutic potential of cannabinoid CB2 receptor inverse agonists
C A Lunn, E-P Reich, J S Fine, B Lavey, J A Kozlowski, R W Hipkin, D J Lundell and L Bober
Br J Pharmacol 153: 226-239; advance online publication, October 1, 2007; doi:10.1038/sj.bjp.0707480
See also: Commentary by Mackie & RossCB2 receptors in the brain: role in central immune function FREE
G A Cabral, E S Raborn, L Griffin, J Dennis and F Marciano-Cabral
Br J Pharmacol 153: 240-251; advance online publication, November 26, 2007; doi:10.1038/sj.bjp.0707584
See also: Commentary by Mackie & RossEndocannabinoids and cannabinoid receptors in ischaemia–reperfusion injury and preconditioning FREE
P Pacher and G Haskó
Br J Pharmacol 153: 252-262; advance online publication, November 19, 2007; doi:10.1038/sj.bjp.0707582
See also: Commentary by Mackie & RossCannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation FREE
K L Wright, M Duncan and K A Sharkey
Br J Pharmacol 153: 263-270; advance online publication, October 1, 2007; doi:10.1038/sj.bjp.0707486
See also: Commentary by Mackie & RossDirect suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptor FREE
B N Dittel
Br J Pharmacol 153: 271-276; advance online publication, October 8, 2007; doi:10.1038/sj.bjp.0707493
See also: Commentary by Mackie & RossCannabinoid CB2 receptors in human brain inflammation FREE
C Benito, R M Tolón, M R Pazos, E Núñez, A I Castillo and J Romero
Br J Pharmacol 153: 277-285; advance online publication, October 15, 2007; doi:10.1038/sj.bjp.0707505
See also: Commentary by Mackie & RossCB2 receptors as new therapeutic targets for liver diseases FREE
S Lotersztajn, F Teixeira-Clerc, B Julien, V Deveaux, Y Ichigotani, S Manin, J Tran-Van-Nhieu, M Karsak, A Zimmer and A Mallat
Br J Pharmacol 153: 286-289; advance online publication, October 22, 2007; doi:10.1038/sj.bjp.0707511
See also: Commentary by Mackie & RossCannabinoid receptors in acute and chronic complications of atherosclerosis FREE
F Mach, F Montecucco and S Steffens
Br J Pharmacol 153: 290-298; advance online publication, October 29, 2007; doi:10.1038/sj.bjp.0707517
See also: Commentary by Mackie & RossCB2 receptor-mediated migration of immune cells: it can go either way FREE
A M Miller and N Stella
Br J Pharmacol 153: 299-308; advance online publication, November 5, 2007; doi:10.1038/sj.bjp.0707523
See also: Commentary by Mackie & RossThe peripheral cannabinoid receptor knockout mice: an update FREE
N E Buckley
Br J Pharmacol 153: 309-318; advance online publication, October 29, 2007; doi:10.1038/sj.bjp.0707527
See also: Commentary by Mackie & RossCannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain FREE
J Guindon and A G Hohmann
Br J Pharmacol 153: 319-334; advance online publication, November 12, 2007; doi:10.1038/sj.bjp.0707531
See also: Commentary by Mackie & RossTargeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands FREE
A Poso and J W Huffman
Br J Pharmacol 153: 335-346; advance online publication, November 5, 2007; doi:10.1038/sj.bjp.0707567
See also: Commentary by Mackie & RossNeuropharmacology
Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI
C-L Chin, A E Tovcimak, V P Hradil, T R Seifert, P R Hollingsworth, P Chandran, C Z Zhu, D Gauvin, M Pai, J Wetter, G C Hsieh, P Honore, J M Frost, M J Dart, M D Meyer, B B Yao, B F Cox and G B Fox
Br J Pharmacol 153: 367-379; advance online publication, October 29, 2007; doi:10.1038/sj.bjp.0707506
Abstract | First page | Full Text | PDF
See also: Commentary by Mackie & RossCompartmentalization of endocannabinoids into lipid rafts in a dorsal root ganglion cell line
N Rimmerman, H V Hughes, H B Bradshaw, M X Pazos, K Mackie, A L Prieto and J M Walker
Br J Pharmacol 153: 380-389; advance online publication, October 29, 2007; doi:10.1038/sj.bjp.0707561
Abstract | First page | Full Text | PDF
See also: Commentary by MaccarroneSee also: Commentary by Mackie & RossIn vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models
B B Yao, G C Hsieh, J M Frost, Y Fan, T R Garrison, A V Daza, G K Grayson, C Z Zhu, M Pai, P Chandran, A K Salyers, E J Wensink, P Honore, J P Sullivan, M J Dart and M D Meyer
Br J Pharmacol 153: 390-401; advance online publication, November 12, 2007; doi:10.1038/sj.bjp.0707568
Abstract | First page | Full Text | PDF
See also: Commentary by Mackie & RossCardiovascular and pulmonary pharmacology
CB2 cannabinoid receptor agonists attenuate TNF-
-induced human vascular smooth muscle cell proliferation and migration
M Rajesh, P Mukhopadhyay, G Haskó, J W Huffman, K Mackie and P Pacher
Br J Pharmacol 153: 347-357; advance online publication, November 12, 2007; doi:10.1038/sj.bjp.0707569
Abstract | First page | Full Text | PDF
See also: Commentary by Mackie & RossImmunopharmacology and inflammation
In vivo effects of CB2 receptor-selective cannabinoids on the vasculature of normal and arthritic rat knee joints
J J McDougall, V Yu and J Thomson
Br J Pharmacol 153: 358-366; advance online publication, November 5, 2007; doi:10.1038/sj.bjp.0707565
Abstract | First page | Full Text | PDF
See also: Commentary by Mackie & Ross
